Source: Fierce Pharma The verdict is in: The FDA has approved Biogen’s controversial Alzheimer’s treatment aducanumab. The FDA’s approval on Monday is set to cause a ripple effect among drugmakers and researchers studying the elusive disease, the sixth leading cause of death in the U.S., and comes after months of intense controversy over…...